DekaBank Deutsche Girozentrale bought a new stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 7,400 shares of the company’s stock, valued at approximately $127,000.

Several other hedge funds have also recently made changes to their positions in EDIT. Paulson & CO. Inc. purchased a new stake in shares of Editas Medicine during the first quarter valued at approximately $1,116,000. State Street Corp increased its stake in shares of Editas Medicine by 2.4% in the fourth quarter. State Street Corp now owns 105,167 shares of the company’s stock valued at $1,708,000 after buying an additional 2,476 shares in the last quarter. UBS Group AG increased its stake in shares of Editas Medicine by 747.7% in the first quarter. UBS Group AG now owns 78,217 shares of the company’s stock valued at $1,746,000 after buying an additional 68,990 shares in the last quarter. Driehaus Capital Management LLC increased its stake in shares of Editas Medicine by 169.8% in the first quarter. Driehaus Capital Management LLC now owns 125,684 shares of the company’s stock valued at $2,805,000 after buying an additional 79,104 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Editas Medicine during the fourth quarter valued at approximately $1,479,000. Institutional investors own 70.17% of the company’s stock.

Editas Medicine, Inc. (EDIT) opened at 21.26 on Thursday. The firm’s 50-day moving average is $17.75 and its 200-day moving average is $19.12. Editas Medicine, Inc. has a 12 month low of $12.43 and a 12 month high of $29.20. The company’s market cap is $870.09 million.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.01. The company had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $2.20 million. Editas Medicine had a negative net margin of 2,091.36% and a negative return on equity of 67.75%. The firm’s revenue was down 8.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.54) earnings per share. On average, analysts anticipate that Editas Medicine, Inc. will post ($2.84) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “DekaBank Deutsche Girozentrale Buys New Position in Editas Medicine, Inc. (EDIT)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/dekabank-deutsche-girozentrale-buys-new-position-in-editas-medicine-inc-edit/1533108.html.

Several analysts have recently commented on EDIT shares. Cann started coverage on shares of Editas Medicine in a report on Monday, July 17th. They issued a “market perform” rating for the company. Zacks Investment Research upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Wednesday, July 12th. J P Morgan Chase & Co set a $27.00 price target on shares of Editas Medicine and gave the company a “hold” rating in a research report on Wednesday, August 9th. SunTrust Banks, Inc. started coverage on shares of Editas Medicine in a research report on Thursday, July 13th. They set a “hold” rating and a $17.00 price target for the company. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Editas Medicine in a research report on Tuesday, July 18th. Five analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $25.03.

In related news, insider Gerald Frank Cox purchased 4,000 shares of Editas Medicine stock in a transaction that occurred on Friday, June 2nd. The stock was bought at an average cost of $14.15 per share, for a total transaction of $56,600.00. Following the completion of the transaction, the insider now owns 4,000 shares in the company, valued at $56,600. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Boris Nikolic purchased 35,000 shares of Editas Medicine stock in a transaction that occurred on Friday, June 2nd. The shares were bought at an average price of $14.07 per share, with a total value of $492,450.00. Following the completion of the transaction, the director now owns 35,000 shares of the company’s stock, valued at approximately $492,450. The disclosure for this purchase can be found here.

About Editas Medicine

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.